Breaking News Instant updates and real-time market news.

ABT

Abbott

$86.61

1.02 (1.19%)

, AMRN

Amarin

$14.77

-3.04 (-17.07%)

04:55
08/12/19
08/12
04:55
08/12/19
04:55

American Association of Diabetes Educators to hold annual meeting

Annual Meeting of AADE 2019 will be held in Houston, Texas on August 9-12.

ABT

Abbott

$86.61

1.02 (1.19%)

AMRN

Amarin

$14.77

-3.04 (-17.07%)

AZN

AstraZeneca

$44.78

0.64 (1.45%)

BSX

Boston Scientific

$43.20

0.44 (1.03%)

CL

Colgate-Palmolive

$71.51

-0.18 (-0.25%)

CORT

Corcept Therapeutics

$12.42

-0.01 (-0.08%)

DRIO

DarioHealth

$0.54

-0.06 (-10.00%)

DXCM

DexCom

$155.42

1.22 (0.79%)

DVAX

Dynavax

$3.38

0.34 (11.18%)

LLY

Eli Lilly

$113.74

-0.13 (-0.11%)

PODD

Insulet

$152.43

6.75 (4.63%)

MNKD

MannKind

$1.10

0.02 (1.86%)

MDT

Medtronic

$101.63

-0.64 (-0.63%)

MRK

Merck

$85.51

0.75 (0.88%)

NVO

Novo Nordisk

$50.27

-0.4 (-0.79%)

RHHBY

Roche

$0.00

(0.00%)

SNY

Sanofi

$41.56

-0.18 (-0.43%)

SLXP

Bought by VRX

$0.00

(0.00%)

SIEGY

Siemens

$0.00

(0.00%)

SENS

Senseonics

$1.18

0.075 (6.82%)

TATYY

Tate & Lyle

$0.00

(0.00%)

TNDM

TNDM

XERS

Xeris Pharmaceuticals

$10.74

-0.59 (-5.21%)

  • 12

    Aug

  • 12

    Aug

  • 13

    Aug

  • 15

    Aug

  • 18

    Aug

  • 19

    Aug

  • 26

    Aug

  • 02

    Sep

  • 04

    Sep

  • 05

    Sep

  • 09

    Sep

  • 10

    Sep

  • 12

    Sep

  • 16

    Sep

  • 16

    Sep

  • 20

    Sep

  • 23

    Sep

  • 25

    Sep

  • 28

    Sep

  • 02

    Oct

  • 10

    Oct

  • 23

    Oct

  • 29

    Oct

  • 04

    Nov

  • 13

    Nov

ABT Abbott
$86.61

1.02 (1.19%)

04/29/19
PIPR
04/29/19
NO CHANGE
Target $165
PIPR
Overweight
Piper reiterates Overweight on DexCom after 'robust' teen survey results
There were 8,042 responses to Piper Jaffray's teen survey in February and March, of which 1,707 have diabetes or a member of their household does, analyst JP McKim tells investors in a research note. The survey implies underlying continuous glucose monitoring market growth of close to 58%, says the analyst. Abbott (ABT) reported 70% Libre growth in Q1 and DexCom (DXCM) reports May 1, McKim points out. He expects "continued strong growth" from DexCom following the "robust" survey results and reiterates an Overweight rating on the shares with a $165 price target.
07/18/19
BMOC
07/18/19
NO CHANGE
Target $94
BMOC
Outperform
Abbott price target raised to $94 from $87 at BMO Capital
BMO Capital analyst Joanne Wuensch raised her price target on Abbott to $94 and kept her Outperform rating after its Q2 earnings beat and a raise in FY19 guidance, saying the company is among a "handful" of medtech names that deliver above-market revenue and double-digit earnings growth along with operating leverage. The analyst notes that following its AbbVie spinoff and acquisition of St. Jude Medical and Alere, Abbott's growth drivers of Alinity, Libre and MitraClip are "humming along" - a trend she expects to continue.
07/18/19
COWN
07/18/19
NO CHANGE
Target $95
COWN
Outperform
Abbott price target raised to $95 from $86 at Cowen
Cowen analyst Joshua Jennings raised his price target on Abbott to $95 from $86 following Q2 earnings. The analyst said the quarter's highlight was the organic sales growth of 7.5% which was above its target of 7.0%, reflecting continued strength for Libre, MitraClip, and Alinity. He noted management raised it guidance for organic sales growth and earnings and he believes the company can continue to post above consensus results in the second half of the year. Jennings reiterated his Outperform rating on Abbott shares.
07/18/19
JEFF
07/18/19
NO CHANGE
Target $98
JEFF
Buy
Abbott price target raised to $98 from $80 at Jefferies
Jefferies analyst Raj Denhoy raised his price target for Abbott Laboratories to $98 from $80 saying the company's growth story is "still going strong" following its Q2 results. The quarter is more proof that the pharma exit and medtech "double-down" was right move, Denhoy tells investors in a research note. Despite Abbott's "strong" current momentum, each product cycle is still in early innings, adds the analyst. He keeps a Buy rating on the shares.
AMRN Amarin
$14.77

-3.04 (-17.07%)

08/09/19
CANT
08/09/19
NO CHANGE
Target $35
CANT
Overweight
Amarin selloff on surprise FDA panel meeting overdone, says Cantor Fitzgerald
Amarin's announcement last night that the FDA plans to hold an advisory committee meeting, tentatively scheduled for November 14, came as a surprise, Cantor Fitzgerald analyst Louise Chen tells investors in a research note titled "No Heartbreak Here, Negative Reaction To AdCom Is Overdone, In Our View." That being said, the stock weakness in reaction to the news is overdone, says Chen. Amarin shares are down 21%, or $3.66, to $14.15 in premarket trading. The potential three-month extension to the FDA action date does not impact Vascepa's potentially multi-billion dollar peak sales opportunity, argues the analyst. Chen keeps an Overweight rating on Amarin with a $35 price target.
08/09/19
HCWC
08/09/19
NO CHANGE
Target $51
HCWC
Buy
Amarin FDA panel driven by agency's conservative approach, says H.C. Wainwright
The FDA's decision to host an Advisory Committee meeting could be driven more by the agency's conservative approach to an expanded cardiovascular event risk reduction label potentially impacting tens of millions of Americans, than any immediate concerns regarding Amarin's REDUCE-IT results themselves, H.C. Wainwright analyst Andrew Fein tells investors in a research note. Management noted the expanded Vascepa label has the potential to be the first indication to impact as many as a third of American adults, and along these lines the FDA holding an AdCom "represents vigilance above all else," contends the analyst. He continues to emphasize that the current stage of commercial development "could potentially represent just the tip of the iceberg for Vascepa." Fein downplays the significance of the AdCom in terms of "materially influencing" the overall approval path for Vascepa's expanded label and reiterates his belief of Vascepa "as a game changing drug." He believes the AdCom timing can be quantifiably valued and is "only worth" approximately a $2-$3 potential hit to his price target of $51. Fein reiterates a Buy rating on Amarin.
08/09/19
JEFF
08/09/19
NO CHANGE
Target $30
JEFF
Buy
Amarin selloff on FDA panel a buying opportunity, says Jefferies
Jefferies analyst Michael Yee views today's selloff in shares of Amarin as a buying opportunity. It is reasonable to have a drug this big discussed in public forum, Yee tells investors in a research note. While the FDA panel brings "some new risk," the corresponding stock selloff more than reflecting this, says Yee. He sees a "buying opportunity since approval is very likely." Yee reiterates a Buy rating on Amarin with a $30 price target.
08/01/19
SBSH
08/01/19
NO CHANGE
Target $23
SBSH
Buy
Amarin shares already pricing in Vascepa label expansion, says Citi
Citi analyst Joel Beatty agrees with Amarin that an FDA panel for the Vascepa label expansion is unlikely given that less than two months remain until the action date of September 28. However, approval of a cardiovascular risk reduction claim for Vascepa is already priced in to the stock, Beatty tells investors in a research note. As such, the analyst does not expect much stock movement around the PDUFA date. Upside would be if a very broad label is granted, such as no triglyceride level cutoff, says Beatty. The analyst believes that for Amarin shares to reach his unchanged price target of $23, Vascepa sales need to reach his 2020 sales projection of $769M, which is a 91% increase above the current annual run rate of $401M. This is realistic, however, given the direct-to-consumer advertising planned to begin in Q2 of 2020, as many primary care physicians "relatively unfamiliar" with Vascepa will begin to be repeatedly asked about it by patients, contends the analyst. He keeps a Buy rating on Amarin. The stock closed Wednesday up 15c to $18.59.
AZN AstraZeneca
$44.78

0.64 (1.45%)

07/26/19
HCWC
07/26/19
NO CHANGE
HCWC
Amarin prepared to defend patents against Epanova launch, says H.C. Wainwright
After speaking with an intellectual property attorney, H.C. Wainwright analyst Andrew Fein believes Amarin (AMRN) has prepared itself to defend its patents for Vascepa against a possible launch of AstraZeneca's (AZN) omega-3 Epanova. The consultation revealed the FDA's Orange Book includes 25 patents listed for Vascepa, Fein tells investors in a research note. While, according to the IP attorney, Amarin's Orange Book patents do not appear to directly address Epanova, Amarin has a large patent portfolio in this space, says the analyst. Fein points out that Amarin could not hypothetically sue AstraZeneca for patent infringement until Epanova was made, used, or sold in a commercial context. These are not brand-generic circumstances between both companies, he writes. However, Fein thinks Amarin's patents could give it the upper hand and he reiterates a Buy rating on the shares with a $51 price target.
07/29/19
WBLR
07/29/19
NO CHANGE
WBLR
Outperform
Updates 'very positive' for upcoming Pieris presentation, says William Blair
Pieris Pharmaceuticals (PIRS) will present Phase Ib safety and efficacy results with PRS-060, an inhaled IL-4R alpha inhibitor, at the upcoming European Respiratory Society International Congress, held September 28 through October 2, William Blair analyst Matt Phipps tells investors in a research note. The poster presentation to be presented on October 1 is titled, "Multiple ascending dose study of the inhaled IL-4Ra antagonist, AZD1402/PRS-060, in mild asthmatics demonstrates robust FeNO reduction and a promising clinical profile for the treatment of asthma," the analyst point out. In addition, AstraZeneca (AZN) plans to initiate a Phase II trial with AZD1402/PRS-060 in the second half of this year, according to its recent earnings presentation, adds Phipps. He views these updates as "very positive" for the upcoming presentation, and believes PRS-060 has "significant potential" in the treatment of asthma patients. Phipps keeps an Outperform rating on Pieris Pharmaceuticals.
07/11/19
RAJA
07/11/19
NO CHANGE
RAJA
Death of drug rebate rule a win for PBMs and distributors, says Raymond James
After multiple media outlets, including Politico, reported that the Trump Administration has decided to withdraw the drug rebate rule, Raymond James analyst Chris Meekins called the news "a win" for pharmacy benefit managers and drug distributors and "a slight negative" for the pharmaceutical makers. The cost of the proposal to the government was ultimately too high with little guarantee that list prices would go down, said Meekins. However, President Trump hinted something "major" on drug pricing was coming over the next week during his kidney care speech and the analyst thinks the President is planning to move forward with an executive order on pricing. Publicly traded pharmaceutical distributors include McKesson (MCK), Cardinal Health (CAH), Amerisource (ABC) and Patterson (PDCO). Owners of pharmacy benefit managers include CVS Health (CVS), UnitedHealth (UNH), Anthem (ANTM) and Cigna (CI). Publicly traded large cap drugmakers include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY).
07/17/19
RAJA
07/17/19
NO CHANGE
RAJA
Investors shouldn't overreact to drug proposal headlines, says Raymond James
Raymond James analyst Chris Meekins noted that President Donald Trump has indicated an Executive Order on drug pricing is coming soon, but he believes investors "should be cautious not to overreact" to drug related proposal headlines as he "cannot think of a single proposal that was finalized and also survived a court challenge resulting in a negative impact on earnings" yet from the Trump Administration. Given the history of the current White House to date, Meekins said he is increasingly skeptical the Administration will get anything meaningful finalized and overcome legal challenges that will impact drugmakers' earnings before the 2020 election, he tells investors in a healthcare policy note. Publicly traded large cap drugmakers include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY).
BSX Boston Scientific
$43.20

0.44 (1.03%)

08/07/19
PIPR
08/07/19
NO CHANGE
PIPR
Piper says FDA update on paclitaxel-coated devices 'likely keeps the status quo'
After the FDA issued an update on its analysis of a late mortality signal in patients treated for peripheral artery disease in the femoropopliteal artery with paclitaxel-coated balloons and paclitaxel-eluting stents, Piper Jaffray analyst Matt O'Brien said the FDA's conclusion "likely keeps the status quo as far as usage in 2019." However, he still sees a significant patency benefit with these devices and expects further clinical data to resolve doctor's concerns in the longer-term, O'Brien stated. Makers of paclitaxel-coated devices include Boston Scientific (BSX) and Medtronic (MDT).
07/24/19
PIPR
07/24/19
NO CHANGE
Target $50
PIPR
Overweight
Boston Scientific second half guidance achievable, says Piper Jaffray
Boston Scientific's Q2 results were essentially in line with consensus estimates as "some concerning areas" from Q1 persisted, such as Neuromod, but were offset by faster growth areas like Medsurg and Structural Heart, Piper Jaffray analyst Matt O'Brien tells investors in a research note. The second half of 2019 acceleration in the core business, implied by the unchanged guidance, is achievable, says the analyst. He reiterates an Overweight rating on Boston Scientific shares with a $50 price target.
07/03/19
FBCO
07/03/19
NO CHANGE
Target $45
FBCO
Outperform
Sales of Boston Scientific's bead business not surprising, says Credit Suisse
Credit Suisse analyst Matt Miksic notes that Boston Scientific (BSX) has agreed to sell its portfolio of drug-loadable microspheres and "bland" embolic bead products for treating arteriovenous malformations and hyper vascular tumors to Varian (VAR) for $90M.The analyst does not view it as surprising, and reiterates an Outperform rating and $45 target on Boston Scientific's shares.
06/27/19
STFL
06/27/19
NO CHANGE
Target $46
STFL
Buy
Boston Scientific price target raised to $46 after analyst day at Stifel
Stifel analyst Rick Wise said Boston Scientific hosted a "compelling" analyst day at which the company highlighted an "impressive array of sizable, recently-launched and future pipeline opportunities." The company's 2020-2022 targets are largely in-line with his and current consensus estimates and he senses this guidance is "highly achievable, if not conservative," Wise stated following the event. The analyst, who left his estimates largely unchanged but said he feels increasingly confident about his long-term projections, maintains a Buy rating on Boston Scientific with a price target of $46, up from $44 previously.
CL Colgate-Palmolive
$71.51

-0.18 (-0.25%)

04/29/19
04/29/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Target (TGT) upgraded to Overweight from Equal Weight at Barclays with analyst Matthew McClintock saying Target is taking market share from a "much weaker" retailer subset than other positive traffic retailers. 2. Sprouts Farmers Market (SFM) upgraded to Buy from Hold at Deutsche Bank. 3. American Airlines (AAL) upgraded to Buy from Hold at Deutsche Bank with analyst Michael Linenberg saying American's lowering of its earnings guidance range last week was not unexpected given the recent rise in fuel prices and grounding of its MAX fleet. The analyst thinks the resetting of expectations by management establishes a "floor" for American's share price and provides the company a bit more "cushion" around its earnings targets. 4. Colgate-Palmolive (CL) upgraded to Neutral from Underweight at JPMorgan with analyst Andrea Teixeira saying the company's organic growth is "finally starting to show consistent improvement," despite mixed signals from most recent scanner data in the U.S. 5. Adobe (ADBE) upgraded to Overweight from Equal Weight at Morgan Stanley with analyst Keith Weiss saying his field work, meetings with management and analysis of segment contribution margins have boosted his confidence in Adobe's ability to sustain EPS growth of over 20%, even if he assumes decelerating Digital Media growth. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
04/29/19
JEFF
04/29/19
NO CHANGE
Target $73
JEFF
Hold
Colgate-Palmolive price target raised to $73 from $61 at Jefferies
Jefferies analyst Kevin Grundy raised his price target for Colgate-Palmolive to $73 from $61 following the company's "solid" Q1 results. While a recovery in China will take time, Colgate-Palmolive is "importantly seeing progress" across key markets, including the U.S. and Latin America, and the Colgate Total relaunch is progressing in-line with expectations, Grundy tells investors in a research note. He views the company's sales recovery as "encouraging," but thinks the stock's current valuation limits upside potential. As such, he keeps a Hold rating on Colgate-Palmolive.
06/11/19
ARGS
06/11/19
NO CHANGE
Target $82
ARGS
Buy
Colgate-Palmolive price target raised to $82 from $72 at Argus
Argus analyst Chris Graja raised his price target on Colgate-Palmolive to $82 and kept his Buy rating. The analyst cites the company's 2.4% dividend yield exceeding the 10-year Treasury note payout and expects that dividend to continue to increase. Graja also points to Colgate-Palmolive's accelerating organic sales growth in Q1 to 3% from 2% in Q4 driven by the management's more aggressive advertising initiatives, greater e-commerce product availability, and the company's high financial strength rating relative to his coverage universe.
04/29/19
JPMS
04/29/19
UPGRADE
Target $70
JPMS
Neutral
JPMorgan upgrades Colgate-Palmolive to Neutral on improved sales growth
JPMorgan analyst Andrea Teixeira upgraded Colgate-Palmolive to Neutral from Underweight and raised her price target for the shares to $70 from $62. The company's organic growth is "finally starting to show consistent improvement," despite mixed signals from most recent scanner data in the U.S., Teixeira tells investors in a research note. For the first time in two years, Colgate-Palmolive delivered both volume and pricing growth when reporting quarterly results on Friday, says the analyst. She notes that while the company's global market share losses on a year-over-year basis are still lingering, its market share has been more stable sequentially.
CORT Corcept Therapeutics
$12.42

-0.01 (-0.08%)

02/01/19
RILY
02/01/19
DOWNGRADE
RILY
Neutral
Corcept Therapeutics downgraded to Neutral from Buy at B. Riley FBR
02/05/19
RILY
02/05/19
NO CHANGE
Target $12
RILY
Neutral
Corcept overhang unlikely to lift despite 'helpful' response, says B. Riley FBR
B. Riley FBR analyst David Buck reiterates a Neutral rating on shares of Corcept Therapeutics with an $11 price target following another short seller report as well as response from the company. Negative commentary from short-seller reports have raised a number of issues, including off-label promotion, bribing physicians through speaker fees or otherwise to prescribe Korlym, questioning the efficacy of Korlym and using the FDA's adverse event reporting database to taint the drug as dangerous, and the possible overstatement of sales from the Veteran's Administration channel, Buck tells investors in an intraday research note. He believes Corcept's response this morning to the allegations is "helpful," but he does not expect the overhang to lift immediately from the shares. The stock in midday trading is up 3%, or 32c, to $10.52.
02/01/19
CANT
02/01/19
DOWNGRADE
Target $14
CANT
Neutral
Corcept Therapeutics downgraded to Neutral from Overweight at Cantor Fitzgerald
Cantor Fitzgerald analyst Charles Duncan downgraded Corcept Therapeutics to Neutral and lowered his price target for the shares to $14 from $20. The company's lower than projected Korlym revenue for Q4 and 2019 guidance points to limited upside potential, Duncan tells investors in a post-earnings research note. Further, the analyst says investors need visibility on relacorilant.
02/01/19
RILY
02/01/19
DOWNGRADE
Target $12
RILY
Neutral
B. Riley FBR downgrades Corcept to Neutral on Q4 sales miss
B. Riley FBR analyst David Buck downgraded Corcept Therapeutics to Neutral from Buy and cut his price target for the shares to $12 from $22. The analyst cites the company's "disappointing" preliminary Q4 sales for the downgrade. The stock in midday trading is down 10%, or $1.16, to $10.02.
DRIO DarioHealth
$0.54

-0.06 (-10.00%)

06/06/19
CHLM
06/06/19
INITIATION
Target $1.5
CHLM
Buy
DarioHealth initiated with a Buy at Craig-Hallum
Craig-Hallum analyst Alex Nowak initiated DarioHealth with a Buy rating and $1.50 price target, calling the stock the only public "pure-play" on digital therapeutics for Type 2 Diabetes.
DXCM DexCom
$155.42

1.22 (0.79%)

08/01/19
JPMS
08/01/19
NO CHANGE
Target $190
JPMS
Overweight
DexCom price target raised to $190 from $170 at JPMorgan
JPMorgan analyst Robbie Marcus raised his price target for DexCom to $190 from $170 saying the company last night posted "another very strong quarter." Dexcom generated record new patient adds in all lines of business, Marcus told investors earlier in a research note. Further, the analyst thinks management's increased guidance leaves "enough cushion to continue the beat and raise momentum." He keeps an Overweight rating on DexCom shares.
08/01/19
ADAM
08/01/19
NO CHANGE
Target $185
ADAM
Buy
DexCom price target raised to $185 from $160 at Canaccord
Canaccord analyst Kyle Rose raised his price target on DexCom to $185 from $160 following stellar Q1 results. The analyst cited strong growth in sensor volumes, increased global adoption of CGM, and the ongoing uptake of the G6. He noted the company is on track to double G6 production capacity by the end of 2019 while the company continues to invest in the G7 which remains on track for a limited launch in late 2020. Rose reiterated his Buy rating on DexCom shares.
08/01/19
COWN
08/01/19
NO CHANGE
Target $175
COWN
Outperform
DexCom a core long-term holding, says Cowen
Cowen analyst Doug Schenkel noted DexCom posted another beat and raise quarter with particularly impressive patient commentary. The analyst believes Libre 2 will likely be approved shortly but regardless, he believes the company is poised to continue to materially exceed expectations. He said he would be a buyer of any weakness in the second half of the year and it should remain a long-term core holding. Schenkel reiterated his Outperform rating and $175 price target on DexCom shares.
08/01/19
PIPR
08/01/19
NO CHANGE
PIPR
Overweight
Piper says nonprofit's survey positive for Tandem, DexCom, Insulet
Piper Jaffray analyst JP McKim noted that T1D Exchange, a nonprofit research organization, released its findings of a survey of Type 1 Diabetes patients. The survey results lead him to believe "there is plenty of growth just in the Type 1 market ahead" for Dexcom (DXCM), to be followed by the G7 launch, which will "help unlock the Type 2 market." The survey also points to "an unprecedented level of market share taking" by Tandem (TNDM) in the first 6 months of the year and was positive for Insulet (PODD) as well, McKim tells investors. He has Overweight ratings on all three stocks mentioned.
DVAX Dynavax
$3.38

0.34 (11.18%)

06/18/19
BMOC
06/18/19
NO CHANGE
Target $5
BMOC
Outperform
VBI Vaccines price target lowered to $5 from $12 at BMO Capital
BMO Capital analyst Do Kim lowered his price target on VBI Vaccines (VBIV) to $5, saying that while the company's Sci-B-Vac Phase 3 data met co-primary endpoints showing superior efficacy over Engerix-B, it missed on a secondary for non-inferiority after two doses versus three-dose Engerix. The analyst notes that his lowered estimates reflect a "more equal share" among the low-responder population with Dynavax's (DVAX) Heplisav-B, which is two doses. Do Kim also keeps his Outperform rating on VBI Vaccines while acknowledging that the company has financing needs before Sci-B-Vac approval.
05/24/19
RBCM
05/24/19
NO CHANGE
Target $13
RBCM
Outperform
Dynavax price target lowered to $13 from $19 at RBC Capital
RBC Capital analyst Brian Abrahams lowered his price target on Dynavax to $13 after the company's announced restructuring to de-emphasize oncology, including its SD-101 assets, in favor of its HBV vaccine. The analyst states that a partnership would have been a better outcome for its SD-101 program, but now sees that possibility as unlikely. Abrahams still keeps his Outperform rating on Dynavax shares and believes that a reset in the management's focus should be bet with "good investor receptivity."
07/10/19
CANT
07/10/19
UPGRADE
CANT
Overweight
Dynavax upgraded to Overweight from Neutral at Cantor Fitzgerald
05/24/19
COWN
05/24/19
NO CHANGE
Target $30
COWN
Outperform
Dynavax 'dramatically undervalued' given Heplisav's potential, says Cowen
Cowen analyst Phil Nadeau noted that Dynavax has restructured to focus on the commercialization of Heplisav and will seek strategic alternatives for the future development of its immunooncology programs, including SD-101. The analyst, whose model had no assumptions for SD-101 product revenue, said he continues to think Dynavax shares are "dramatically undervalued" given the potential of Heplisav in HBV and he also believes the company has sufficient cash to make it a success. He keeps an Outperform rating and $30 price target on Dynavax.
LLY Eli Lilly
$113.74

-0.13 (-0.11%)

07/17/19
MZHO
07/17/19
NO CHANGE
Target $103
MZHO
Buy
Amgen seen by Mizuho as 'most likely' buyer of Celgene's Otezla
In the wake of the recent announcement that Bristol-Myers (BMY) plans to divest Otezla as part of its deal to acquire Celgene (CELG), Mizuho analyst Salim Syed said he has received questions on who could be a realistic buyer. He believes the "most likely" buyer would be Amgen (AMGN), followed by Johnson & Johnson (JNJ), which he would label as a "likely" buyer. Syed identifies the "less likely, but possible" buyers as Eli Lilly (LLY) and Regeneron (REGN). The analyst, who said Otezla is worth anywhere from $5B-$10B depending on the view of sales and synergy potential, keeps a Buy rating and $103 price target on Celgene shares.
06/11/19
JPMS
06/11/19
NO CHANGE
JPMS
Overweight
Eli Lilly Rewind data missed 'fairly high' expectations, says JPMorgan
JPMorgan analyst Chris Schott is not surprised by the weakness yesterday in shares of Eli Lilly as he believes the Rewind data came in below "fairly high" expectations. However, the analyst ultimately sees the data confirming a cardiovascular benefit for Trulicity and supporting "continued strong Trulicity/GLP-1 uptake." Further, Schott sees the tirzepatide data at the American Diabetes Association conference as continuing to highlight a potentially best in class efficacy profile for the product. Lilly remains the analyst's top pick in his pharma coverage.
PODD Insulet
$152.43

6.75 (4.63%)

08/06/19
BTIG
08/06/19
NO CHANGE
Target $140
BTIG
Buy
Insulet price target raised to $140 from $130 at BTIG
BTIG analyst Sean Lavin raised his price target on Insulet to $140 and kept his Buy rating after its Q2 results and above-consensus Q3 guidance, saying the company is benefiting from "strong drivers" and the growing demand for diabetes technology, including both CGMs and insulin pumps. The analyst further cites Insulet's release of its new DASH platform and its "no-commitment" adoption model along with expanded payor coverage and its move toward the pharmacy channel combining to improve the ease of access to its technology for patients and payors.
08/06/19
RAJA
08/06/19
NO CHANGE
Target $135
RAJA
Outperform
Insulet price target raised to $135 from $125 at Raymond James
Raymond James analyst Jayson Bedford raised his price target for Insulet to $135 from $125 and maintained an Outperform rating, saying the company generated significant momentum in the second quarter and the revenue beat was the company's largest in over two years. In a research note to investors, Bedford says it is "tough to poke holes" in Q2, and says the raised guidance implies continued momentum. The analyst notes that Horizon, and possibly Tidepool, launching in late 2020 provides visibility into additional growth drivers, giving him confidence in the sustainability of the underlying growth profile.
08/06/19
JEFF
08/06/19
NO CHANGE
Target $140
JEFF
Buy
Insulet price target raised to $140 from $105 at Jefferies
Jefferies analyst Raj Denhoy raised his price target for Insulet to $140 from $105 saying Omnipod adoption "remains hot" following the company's better than expected Q2 results. The launch of Dash, the accompanying move to pharmacy benefit, and the general adoption of technology broadly in diabetes continue to spur growth, Denhoy tells investors in a research note. The analyst raised his estimates and keeps a Buy rating on Insulet.
08/06/19
BMOC
08/06/19
NO CHANGE
Target $150
BMOC
Outperform
Insulet price target raised to $150 from $130 at BMO Capital
BMO Capital analyst Joanne Wuensch raised her price target on Insulet to $150 and kept her Outperform rating after its Q2 results and above-consensus Q3 guidance, saying the company continues a streak of beat-and-raise quarters among diabetes management companies. The analyst further cites Insulet's 4th consecutive quarter of revenue growth over 20% and points to its Horizon artificial pancreas system coming online by the end of 2020, with added benefits coming from the company's international direct sales efforts.
MNKD MannKind
$1.10

0.02 (1.86%)

03/04/19
03/04/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. MannKind (MNKD) initiated with an Outperform at SVB Leerink. 2. Invitae (NVTA) initiated with a Buy at Chardan. 3. Immunomedics (IMMU) initiated with a Buy at H.C. Wainwright. 4. Canopy Growth (CGC) initiated with a Neutral at Melius Research. 5. Alector (ALEC) initiated with an Overweight at Morgan Stanley and Barclays, an Outperform at SVB Leerink and Cowen, as well as a Buy at BofA/Merrill. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
05/14/19
BTIG
05/14/19
INITIATION
Target $3
BTIG
Buy
MannKind initiated with a Buy, $3 price target at BTIG
BTIG analyst Robert Hazlett initiated coverage of MannKind with a Buy rating and $3 price target. The stock closed Monday down 2c to $1.23. With the advancements of continuous glucose monitor technologies, tighter glycemic control will become more of a focus, and MannKind's Afrezza "can play a material role," Hazlett tells investors in a research note. The analyst estimates inhaled insulin Afrezza's peak U.S. sales at greater than $350M. Mannkind's recently revamped management is attempting to energize Afrezza through publications of differentiating data, which can improve acceptance among physicians and patients, helping "solid growth continue," according to Hazlett.
05/14/19
05/14/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. MannKind (MNKD) initiated with a Buy, $3 price target at BTIG. 2. Ross Stores (ROST) and TJX (TJX) initiated with an Outperform at Baird. 3. Elastic (ESTC) initiated with a Hold at Stifel. 4. CytomX Therapeutics (CTMX) initiated with an Overweight at Cantor Fitzgerald. 5. FIS (FIS) initiated with a Buy at BofA/Merrill. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
05/08/19
HCWC
05/08/19
NO CHANGE
Target $3
HCWC
Buy
MannKind price target lowered to $3 from $4 at H.C. Wainwright
H.C. Wainwright analyst Oren Livnat lowered his price target for MannKind to $3 from $4 saying that while Q2 is already shaping up better than Q1, the slower Afrezza ramp drives an estimate reduction. The analyst, however, still believes MannKind's pipeline "is all potential upside" to his model. He keeps a Buy rating on the shares.
MDT Medtronic
$101.63

-0.64 (-0.63%)

07/11/19
LEHM
07/11/19
NO CHANGE
Target $110
LEHM
Overweight
Medtronic price target raised to $110 from $104 at Barclays
Barclays analyst Kristen Stewart raised her price target for Medtronic to $110 from $104 saying the company's recent debt tender and issuance "modestly helps" its earnings outlook. The analyst keeps an Overweight rating on the shares.
06/14/19
UBSW
06/14/19
NO CHANGE
Target $112
UBSW
Buy
Medtronic price target raised to $112 from $110 at UBS
UBS analyst Matthew Taylor raised his price target on Medtronic to $112 and kept his Buy rating after meeting with it CEO and CFO last week. The analyst notes that the management is "pleased" with the company recent performance as its last year's 11% earnings growth topped its long term target of 8%. Taylor notes that the growth has been driven by operating margin expansion and improving cash flows, with the management also "excited" about the company's product pipeline and "big launches" coming over the next 2 years.
07/11/19
CHLM
07/11/19
NO CHANGE
Target $84
CHLM
Buy
Tandem Diabetes a clear beneficiary of Medtronic recall, says Craig-Hallum
Craig-Hallum analyst Alexander Nowak believes Tandem Diabetes (TNDM) and to a lesser extent Insulet (PODD) are the "clear beneficiaries" of the FDA recalling 189,000 Medtronic (MDT) 600-series pumps. The recall should further assist Tandem's share gains over the next several quarters and perhaps years, Nowak tells investors in a research note. And while UnitedHealth (UNH) has an exclusive contract with Medtronic Diabetes, the recall is further data Tandem can use to negotiate with UnitedHealth and argue for inclusion in its network, adds the analyst. He reiterates a Buy rating on shares of Tandem Diabetes with an $84 price target.
MRK Merck
$85.51

0.75 (0.88%)

07/22/19
OPCO
07/22/19
DOWNGRADE
OPCO
Perform
Oppenheimer downgrades Intec Pharma after 'major setback' of trial miss
As previously reported, Oppenheimer analyst Jay Olson downgraded Intec Pharma (NTEC) to Perform from Outperform after the company announced "a major setback" as the ACCORDANCE study did not achieve statistical superiority to Sinemet on the primary endpoint of reduction in daily OFF time. He noted that the company still has additional opportunities with other drugs, including proprietary partnerships with Novartis (NVS) and Merck (MRK), but said the read across from AP-CD/LD to other AP applications in different diseases is uncertain following this morning's news.
08/07/19
ARGS
08/07/19
NO CHANGE
Target $105
ARGS
Buy
Merck price target raised to $105 from $95 at Argus
Argus analyst David Toung raised his price target on Merck to $105 and kept his Buy rating after its "strong" Keytruda-driven Q2 earnings beat, also boosting his FY19 and FY20 EPS view by 16c and 10c to $4.89 and $5.35 respectively. The analyst sees Merck's "blockbuster" Keytruda drug on track for additional indications in the U.S., Japan, China and Europe, with additional growth drivers coming from its Gardasil, Bridion, Lynparza, and Lenvima programs.
NVO Novo Nordisk
$50.27

-0.4 (-0.79%)

06/11/19
LEHM
06/11/19
UPGRADE
LEHM
Equal Weight
Novo Nordisk upgraded to Equal Weight from Underweight at Barclays
Barclays analyst Emmanuel Papadakis upgraded Novo Nordisk (NVO) to Equal Weight from Underweight and raised his price target for the shares to 325 kronor from 275 kronor. The analyst views competitor updates at the American Diabetes Association conference, specifically from Eli Lilly (LLY), as "underwhelming."
06/20/19
DBAB
06/20/19
DOWNGRADE
DBAB
Hold
Novo Nordisk downgraded to Hold from Buy at Deutsche Bank
Deutsche Bank analyst Richard Parkes downgraded Novo Nordisk to Hold from Buy citing valuation.
06/20/19
06/20/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Novo Nordisk (NVO) downgraded to Hold from Buy at Deutsche Bank with analyst Richard Parkes citing valuation. 2. Shopify (SHOP) downgraded to Neutral from Outperformer at CIBC with analyst Todd Coupland stating that while he is encouraged by the company's product announcements, he believes the upside seen in his investment thesis has now been priced into the stock. 3. Enphase Energy (ENPH) downgraded to Neutral from Buy at H.C. Wainwright with analyst Amit Dayal saying at current levels, the shares are more than adequately pricing in another earnings beat for Q2 and potential guidance raise for 2019. 4. Hershey (HSY) downgraded to Underweight from Neutral at Piper Jaffray with analyst Michael Lavery stating the company has a U.S.-centric portfolio with generally stable sales and earnings growth, but the valuation at current share levels "now looks inconsistent with consensus expectations". 5. Carnival (CCL) downgraded to Market Perform from Outperform at William Blair with analyst Sharon Zackfia noting the company lowered expectations for the remainder of the fiscal year, with constant-currency net yields now expected to be flattish to slightly down in Q3 and down in Q4. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
08/05/19
PART
08/05/19
UPGRADE
PART
Buy
Novo Nordisk upgraded to Buy from Hold at Pareto
RHHBY Roche
$0.00

(0.00%)

07/23/19
JPMS
07/23/19
NO CHANGE
JPMS
Neutral
Competition questions for Biogen, Ions' Spinraza not dissipating soon, says JPMorgan
Following Biogen's (BIIB) quarterly results, JPMorgan analyst Jessica Fye notes that while there seems to be limited second quarter impact to the company's and partner Ions Pharmaceuticals' (IONS) Spinraza from Novartis' (NVS) Zolgensma international revenues were down quarter over quarter for a variety of reasons despite double-digit patient growth. Overall, the analyst maintains her view that Roche (RHHBY) and PTC Therapeutics' (PTCT) Risdiplam represents a key potential competitive threat to Spinraza given the convenience of oral dosing and with filing for Risdiplam anticipated in the second half of 2019, in addition to Zolgensma's launch, Fye does not see questions related to competition for Spinraza dissipating anytime soon. The analyst reiterates a Neutral rating on Ions Pharmaceuticals' shares.
07/23/19
BTIG
07/23/19
INITIATION
Target $46
BTIG
Buy
Adaptive Biotechnologies initiated with a Buy at BTIG
BTIG analyst Amanda Murphy initiated Adaptive Biotechnologies (ADPT) with a Buy rating and a price target of $46, saying the company's "clinical immunomics database" represents its "differentiating asset" and offers "incredible value" to biopharma companies. The analyst further cites Adaptive Biotechnologies' partnership with Roche (RHHBY) that should allow it to develop new diagnostics for early detection of diseases where antigens are unknown and also its "strategic" deal with Microsoft (MSFT), whose machine learning capabilities support its immune medicine platform.
07/26/19
UBSW
07/26/19
UPGRADE
UBSW
Buy
Roche upgraded to Buy from Neutral at UBS
UBS analyst Michael Leuchten upgraded Roche to Buy from Neutral and raised his price target for the shares to CHF 300 from CHF 270. The company's legacy portfolio, built around Herceptin and Rituxan, is showing greater resilience while its "credible" neuroscience pipeline is taking shape, Leuchten tells investors in a research note. As such, he now sees Roche's business model as less challenged.
SNY Sanofi
$41.56

-0.18 (-0.43%)

08/01/19
WEDB
08/01/19
NO CHANGE
Target $17
WEDB
Outperform
Lexicon price target lowered to $17 from $35 at Wedbush
Wedbush analyst Liana Moussatos lowered her price target for Lexicon (LXRX) to $17 from $35 to reflect a reduction in Zynquist sales projections. On July 26, partner Sanofi (SNY) announced the intent to terminate the diabetes partnership for Zynquista, which Lexicon indicated was due to not achieving statistical significance for the primary endpoint of reducing placebo-adjusted HbA1c in T2D patients with stage 3b/4 CKD, she contends, adding that Lexicon commented that there were strong trends favoring Zynquista in these patients and is disputing the termination. Moussatos reiterates an Outperform rating on Lexicon's shares.
07/30/19
SBSH
07/30/19
NO CHANGE
Target $3
SBSH
Buy
Citi cuts Lexicon target to $3 from $15, still sees value in sotagliflozin
Citi analyst Yigal Nochomovitz lowered his price target for Lexicon Pharmaceuticals (LXRX) to $3 from $15 while keeping a Buy rating on the shares. The analyst believes Sanofi's (SNY) decision to terminate the partnership reflects to a greater extent Sanofi's prioritization of the internal pipeline and renewed focus on core areas versus specific liabilities regarding sotagliflozin. He still sees see some value in sotagliflozin and thinks shares of Lexicon are worth $3, well above yesterday's closing price of $1.69.
07/24/19
MSCO
07/24/19
NO CHANGE
MSCO
Warming could create need for up to $125B more vaccinations, says Morgan Stanley
Morgan Stanley analysts led by Matthew Harrison offered a report sizing the impact on biopharma from climate change. They conclude that warmer temperatures are likely to create more hospitable environments for disease transmission and they cite recent research that suggests 385M-725M more people than today may be exposed to infectious diseases such as dengue, Zika, chickungunya, and yellow fever by 2050. They estimate $50B-$125B of incremental vaccinations may be needed, but see the potential for that figure to be as high as $200B with branded pricing of more complicated vaccines. The companies best positioned to benefit from a rising need for infectious disease vaccines include Sanofi (SNY), GlaxoSmithKline (GSK), Moderna (MRNA), Merck (MRK), Johnson & Johnson's (JNJ) Janssen, Pfizer (PFE) and Takeda (TAK), according to Harrison and the team.
07/29/19
PIPR
07/29/19
NO CHANGE
PIPR
Sanofi results show Dupixent is 'killing it,' says Piper Jaffray
Sanofi (SNY) this morning reported Q2 results, including revenue numbers for Dupixent, Praluent, and Kevzara, which it co-markets with Regeneron Pharmaceuticals (REGN), Piper Jaffray analyst Christopher Raymond tells investors in a research note titled "Sanofi Read-Through: Dupixent Killing It." While Praluent missed estimates, Kevzara beat and Dupixent "displayed yet another strong quarter," says Raymond. He keeps an Overweight rating on Regeneron ahead of the company's Q2 results on August 6.
SLXP Bought by VRX
$0.00

(0.00%)

SIEGY Siemens
$0.00

(0.00%)

02/26/19
02/26/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Exact Sciences (EXAS) upgraded to Buy from Neutral at Goldman Sachs by analyst Patrick Donnelly, who said the current momentum of the Cologuard commercial ramp provides "strong basis" for the company's premium valuation while the combination of positive Cologuard catalysts and new product roll-outs provide upside to current levels, even after the stock's 75% rally since the beginning of 2018. Exact Sciences is a "must-own growth stock" given the "clean runway forward that is largely in its control with potential for discovery value in the pipeline outside of Cologuard," the analyst said. 2. Siemens (SIEGY) upgraded to Overweight from Neutral at JPMorgan by analyst Andreas Willi, who sees a relative valuation opportunity after the stock's 27% underperformance over the past two years. He believes investor sentiment can improve "after a period where the story has drifted." 3. Kadmon (KDMN) upgraded to Buy from Neutral at Citi by analyst Robyn Karnauskas, who assigned a 50% probability to KD-025 in chronic graft versus host disease with an unadjusted ~$900M market opportunity. However, upside to the stock will depend on quality of the data likely, Karnauskas said. 4. EverQuote (EVER) upgraded to Buy following Q4 beat at BofA/Merrill by analyst Mat Schindler, who said user growth has re-accelerated, supporting evidence of a turnaround, and thinks estimates are conservative and views the risk/reward as attractive. 5. Ally Financial (ALLY) upgraded to Buy from Hold at Sandler O'Neill by analyst Christopher Donat, who said he believes Ally's near-prime auto finance book is "meaningfully less risky" than Santander Consumer's (SC) book or the unsecured credit cards of Discover (DFS) and Capital One (COF), yet all four stocks trade at similar multiples. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
07/23/19
SOCG
07/23/19
UPGRADE
SOCG
Buy
Siemens upgraded to Buy from Hold at Societe Generale
05/21/19
FBCO
05/21/19
UPGRADE
FBCO
Outperform
Siemens upgraded to Outperform from Neutral at Credit Suisse
Credit Suisse analyst Andre Kukhnin upgraded Siemens to Outperform from Neutral and raised his price target for the shares to EUR 143 from EUR 115.
07/15/19
UBSW
07/15/19
DOWNGRADE
Target $11.5
UBSW
Neutral
General Electric downgraded to Neutral from Buy at UBS
UBS analyst Damian Karas downgraded General Electric (GE) to Neutral and lowered his price target to $11.50 from $13, saying that a "notable" decline in interest rates and the continued weakness in the power market combine toward a "more balanced" upside with downside. The analyst states however that after the 20% relative year-to-date outperformance in the stock price, General Electric will continue its multi-year turnaround and transformation, with the Power segment becoming increasingly more important to investor sentiment given the concerns around China demand and Siemens' (SIEGY) intended listing of their Gas & Power unit.
SENS Senseonics
$1.18

0.075 (6.82%)

07/05/19
RAJA
07/05/19
DOWNGRADE
RAJA
Market Perform
Senseonics downgraded to Market Perform from Outperform at Raymond James
Raymond James analyst Jayson Bedford downgraded Senseonics to Market Perform from Outperform. The analyst says the company's "persistent headwinds" leave him "less patient" with respect to the shares.
07/05/19
07/05/19
NO CHANGE

Fly Intel: Top five analyst actions
Catch up on today's top five analyst actions with this list compiled by The Fly: 1. Teva (TEVA) upgraded to Buy from Hold at Argus with analyst Jason McCarthy saying the company has been making progress in resolving its "numerous challenges" of the past several years. 2. Senseonics (SENS) downgraded to Market Perform from Outperform at Raymond James with analyst Jayson Bedford stating the company's "persistent headwinds" leave him "less patient" with respect to the shares. 3.Omnova Solutions (OMN) downgraded to Hold from Buy at Deutsche Bank with analyst David Begleiter saying he believes Synthomer paid a "fair but full price" to acquire Omnova and that a competing bidder is unlikely to emerge. 4. Mercer (MERC) downgraded to Neutral from Outperformer at CIBC. 5. BASF (BASFY) initiated with a Neutral at Goldman Sachs. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
06/06/19
PIPR
06/06/19
NO CHANGE
PIPR
Senseonics receives FDA claim for Eversense CGM system, says Piper Jaffray
Piper Jaffray analyst JP McKim maintained a Neutral rating and $2.70 price target on Senseonics, while noting that the company "received a non-adjunctive claim for their Eversense CGM system" from the FDA. The analyst said that the claim would allow Eversense "to be used in replacement for finger stick glucose measurements" and added that it "is a needed claim to begin the process to unlock the Medicare population and represents an important stage in their commercialization process."
02/04/19
PIPR
02/04/19
NO CHANGE
Target $2.7
PIPR
Neutral
Piper Jaffray uncertain of benefits from increased Roche access for Senseonics
Piper Jaffray analyst JP Kim kept his Neutral rating and $2.70 price target on Senseonics (SENS) after the company announced an extension of agreement with Roche (RHHBY). The analyst notes that the management is likely willing to trade off the near term price gains for long term volume gain through this deal, but adds that a reset of consensus estimates for sales that would lead to Senseonics becoming a "beat and raise story" is uncertain.
TATYY Tate & Lyle
$0.00

(0.00%)

06/03/19
JEFF
06/03/19
DOWNGRADE
JEFF
Underperform
Tate & Lyle downgraded to Underperform from Hold at Jefferies
Jefferies analyst Martin Deboo downgraded Tate & Lyle to Underperform from Hold and lowered his price target for the shares to 6.20 pounds from 7.20 pounds. The analyst views the valuation as stretched at current share levels.
TNDM TNDM

06/17/19
LSCM
06/17/19
NO CHANGE
Target $100
LSCM
Buy
Lake Street reiterates Buy on Tandem Diabetes with $100 price target
Lake Street analyst Brooks O'Neil says shares of Tandem Diabetes fell sharply last week following the release of positive results from two "critical" studies of the t:slim X2 Insulin Pump with Control-IQ Technology. "This reminds us of the reaction of the stock following the release of exceptional Q1 results delivered by Tandem on April 30, 2019," O'Neil tells investors in a research note. While both industry leaders and upstarts are touting "next generation" platforms, only Tandem has conducted a pivotal trial to prove its next gen system's capabilities, O'Neil adds. He reiterates a Buy rating on the shares with a $100 price target.
08/02/19
OPCO
08/02/19
NO CHANGE
Target $84
OPCO
Outperform
Tandem Diabetes price target raised to $84 from $80 at Oppenheimer
Oppenheimer analyst Steven Lichtman raised his price target for Tandem Diabetes to $84 from $80 following the company's Q2 results, saying sales exceeded expectations significantly, with sales and adjusted EBITDA guidance both raised. In a research note to investors, Lichtman says looking forward, the key drivers in his focus are the launch of Control-IQ in Q4 a now building renewal cycle, international expansion and what he continues to believe is an under-appreciated t:sport opportunity.
XERS Xeris Pharmaceuticals
$10.74

-0.59 (-5.21%)

09/13/18
EAMC
09/13/18
INITIATION
Target $10
EAMC
Sell
Xeris Pharmaceuticals initiated with a Sell at Empire
Empire analyst Dr. Cathey Reese initiated Xeris Pharmaceuticals with a Sell and $10 price target saying its main pipeline product is a stable liquid glucagon in an autoinjector device, which the company filed for an FDA approval in mid-August-2018. Reese said several competitor pipelines, including Eli Lilly's (LLY), are in development for stable liquid glucagon products and the likely approval of Lilly's nasal spray glucagon should make it difficult for Xeris to reach investors' revenue expectations.
06/07/19
MZHO
06/07/19
NO CHANGE
Target $27
MZHO
Buy
Xeris selloff on PDUFA extension a buying opportunity, says Mizuho
Mizuho analyst Difei Yang recommends buying shares of Xeris Pharmaceuticals on weakness from the extension of the FDA action date for Gvoke. The delay is not material, and a number of PDUFA goal date extensions for drug applications have concluded with product approvals, Yang tells investors in a research note. The analyst would buy shares of Xeris, "especially on recent weakness," and reiterates a Buy rating on the name with a $27 price target.

TODAY'S FREE FLY STORIES

GOOG

Alphabet

$1,202.00

25.06 (2.13%)

, GOOGL

Alphabet Class A

$1,204.36

25.67 (2.18%)

12:16
08/19/19
08/19
12:16
08/19/19
12:16
Hot Stocks
Trump says 'Google should be sued' over role in 2016 election »

President Donald Trump…

GOOG

Alphabet

$1,202.00

25.06 (2.13%)

GOOGL

Alphabet Class A

$1,204.36

25.67 (2.18%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Sep

  • 27

    Oct

$NYE

NYSE Market Internals

$0.00

(0.00%)

12:16
08/19/19
08/19
12:16
08/19/19
12:16
Technical Analysis
NYSE market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

APAM

Artisan Partners

$26.64

0.43 (1.64%)

12:14
08/19/19
08/19
12:14
08/19/19
12:14
Conference/Events
Artisan Partners management to meet with Jefferies »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Aug

ARMK

Aramark

$40.72

3.65 (9.85%)

, PCG

PG&E

$10.43

-3.87 (-27.06%)

12:13
08/19/19
08/19
12:13
08/19/19
12:13
On The Fly
Aramark upgrades, PG&E double downgrade among today's top analyst calls »

Check out today's top…

ARMK

Aramark

$40.72

3.65 (9.85%)

PCG

PG&E

$10.43

-3.87 (-27.06%)

CVX

Chevron

$117.16

1.37 (1.18%)

XOM

Exxon Mobil

$69.22

0.92 (1.35%)

BTU

Peabody Energy

$19.31

0.13 (0.68%)

ARLP

Alliance Resource Partners

$14.95

(0.00%)

SONO

Sonos

$13.14

1.24 (10.42%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

QUOT

Quotient Technology

$7.84

0.035 (0.45%)

12:11
08/19/19
08/19
12:11
08/19/19
12:11
Hot Stocks
Elk Creek Partners reports 5.37% passive stake in Quotient Technology »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Sep

  • 12

    Sep

12:05
08/19/19
08/19
12:05
08/19/19
12:05
General news
Treasury's $87 B 3- and 6-month bill auctions were mixed »

Treasury's $87 B 3-…

BMA

Banco Macro

$34.53

-3.75 (-9.80%)

12:00
08/19/19
08/19
12:00
08/19/19
12:00
Hot Stocks
Banco Macro falls -9.8% »

Banco Macro is down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BBAR

BBVA

$5.29

-0.575 (-9.80%)

12:00
08/19/19
08/19
12:00
08/19/19
12:00
Hot Stocks
BBVA falls -10.0% »

BBVA is down -10.0%, or…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PCG

PG&E

$10.29

-4.01 (-28.04%)

12:00
08/19/19
08/19
12:00
08/19/19
12:00
Hot Stocks
PG&E falls -27.9% »

PG&E is down -27.9%,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EL

Estee Lauder

$197.12

17.86 (9.96%)

12:00
08/19/19
08/19
12:00
08/19/19
12:00
Hot Stocks
Estee Lauder rises 9.9% »

Estee Lauder is up 9.9%,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Aug

MYOV

Myovant Sciences

$7.90

0.92 (13.18%)

12:00
08/19/19
08/19
12:00
08/19/19
12:00
Hot Stocks
Myovant Sciences rises 13.1% »

Myovant Sciences is up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NM

Navios Maritime

$4.98

0.58 (13.18%)

12:00
08/19/19
08/19
12:00
08/19/19
12:00
Hot Stocks
Navios Maritime rises 13.3% »

Navios Maritime is up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

REPYY

Repsol

$0.00

(0.00%)

11:56
08/19/19
08/19
11:56
08/19/19
11:56
Downgrade
Repsol rating change  »

Repsol downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MLM

Martin Marietta

$254.47

-0.27 (-0.11%)

11:56
08/19/19
08/19
11:56
08/19/19
11:56
Conference/Events
Martin Marietta management to meet with Jefferies »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Aug

  • 20

    Aug

  • 21

    Aug

  • 13

    Nov

GGAL

Grupo Financiero

$15.57

-2.14 (-12.08%)

11:55
08/19/19
08/19
11:55
08/19/19
11:55
Options
Grupo Financiero put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RDS.A

Royal Dutch Shell

$56.25

0.7 (1.26%)

, RDS.B

Royal Dutch Shell

$56.37

0.815 (1.47%)

11:49
08/19/19
08/19
11:49
08/19/19
11:49
Downgrade
Royal Dutch Shell, Royal Dutch Shell rating change  »

Royal Dutch Shell…

RDS.A

Royal Dutch Shell

$56.25

0.7 (1.26%)

RDS.B

Royal Dutch Shell

$56.37

0.815 (1.47%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

11:37
08/19/19
08/19
11:37
08/19/19
11:37
General news
3-Month Bill Auction Total Amount data reported »

3-Month Bill Auction…

11:37
08/19/19
08/19
11:37
08/19/19
11:37
General news
6-Month Bill Auction Total Amount data reported »

6-Month Bill Auction…

GFF

Griffon

$18.28

0.45 (2.52%)

11:33
08/19/19
08/19
11:33
08/19/19
11:33
Conference/Events
Griffon management to meet with Sidoti »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Aug

  • 22

    Aug

  • 23

    Sep

  • 25

    Sep

SPY

SPDR S&P 500 ETF Trust

$292.26

3.47 (1.20%)

, SPX

S&P 500

$0.00

(0.00%)

11:31
08/19/19
08/19
11:31
08/19/19
11:31
General news
Trump says Fed rate 'should be reduced by at least 100 basis points' »

President Donald Trump…

SPY

SPDR S&P 500 ETF Trust

$292.26

3.47 (1.20%)

SPX

S&P 500

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

APO

Apollo Global

$34.20

2.17 (6.77%)

, TGNA

Tegna

$15.82

0.74 (4.91%)

11:29
08/19/19
08/19
11:29
08/19/19
11:29
Periodicals
Apollo tells Bloomberg didn't approach Tegna about selling stations to Tegna »

A spokesperson for Apollo…

APO

Apollo Global

$34.20

2.17 (6.77%)

TGNA

Tegna

$15.82

0.74 (4.91%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Sep

BSET

Bassett Furniture

$12.48

0.49 (4.09%)

11:25
08/19/19
08/19
11:25
08/19/19
11:25
Conference/Events
Bassett Furniture management to meet with Sidoti »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Aug

UBER

Uber

$35.52

0.3 (0.85%)

, SQ

Square

$64.15

1.24 (1.97%)

11:25
08/19/19
08/19
11:25
08/19/19
11:25
Periodicals
Uber names Melinda Roylett as new U.K. boss, Reuters reports »

Uber (UBER) has appointed…

UBER

Uber

$35.52

0.3 (0.85%)

SQ

Square

$64.15

1.24 (1.97%)

WE

We Company

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Aug

  • 28

    Aug

  • 28

    Aug

  • 10

    Sep

  • 27

    Oct

  • 06

    Nov

WORK

Slack Technologies

$31.00

0.995 (3.32%)

11:25
08/19/19
08/19
11:25
08/19/19
11:25
Options
Slack call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Sep

11:25
08/19/19
08/19
11:25
08/19/19
11:25
General news
FX Action: USD-JPY »

FX Action: USD-JPY…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.